AngioDynamics gets FDA OK for prostate cancer study

06/20/2013 |

AngioDynamics has received investigational device exemption approval from the FDA to conduct a clinical study of its NanoKnife technology, which uses precise ablation to treat patients with localized prostate cancer. The trial will enroll 200 patients from six clinical sites in Europe.

View Full Article in:

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Santa Clara, CA
Food & Drug Associate
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA